{
    "clinical_study": {
        "@rank": "127772", 
        "arm_group": [
            {
                "arm_group_label": "Duloxetine", 
                "arm_group_type": "Experimental", 
                "description": "Starting dose is 30 milligram (mg) duloxetine, then titrate up to 60 mg administered daily by mouth for about 27 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo matches the duloxetine capsule. After 13 weeks administered daily by mouth, then change to duloxetine administered daily by mouth for about 14 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy and safety of duloxetine once daily\n      compared with placebo on the reduction of pain due to osteoarthritis (OA) in knee or hip in\n      participants in China."
        }, 
        "brief_title": "A Study of Duloxetine in Participants With Chronic Pain Due to Osteoarthritis in China", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteoarthritis", 
        "condition_browse": {
            "mesh_term": "Osteoarthritis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Meet clinical and radiographic criteria for the diagnosis of OA of the knee or hip\n             with pain for \u226514 days of each month for 3 months prior to study entry\n\n          -  Have a rating \u22654 on the Brief Pain Inventory (BPI) 24-hour average pain item\n             (Question 3 of the BPI modified short form) at both Screening and Randomization\n\n        Exclusion Criteria:\n\n          -  Have previously completed/withdrawn from this study or any other study investigating\n             duloxetine (Note: Participants who have been previously screened for a duloxetine\n             study other than this study and never received investigational product will be\n             eligible for this study if they meet all current entry criteria)\n\n          -  Have had previous exposure to duloxetine\n\n          -  Have any previous diagnosis of psychosis, bipolar disorder, or schizoaffective\n             disorder\n\n          -  Current (within 1 year of Screening) Diagnostic and Statistical Manual of Mental\n             Disorders, Fourth Edition Axis I diagnosis of major depressive disorder, anxiety\n             disorders (excluding phobias), alcohol or eating disorders, as determined by the\n             Mini-International Neuropsychiatric Interview or a previous diagnosis\n\n          -  Have a history of substance abuse or dependence within the past year, excluding\n             nicotine and caffeine\n\n          -  Are taking any excluded medications that cannot be discontinued at Screening\n\n          -  Have had treatment with a monoamine oxidase inhibitor (MAOI) within 14 days of\n             randomization or the potential need to use an MAOI during the study or within 5 days\n             of discontinuation of investigational product\n\n          -  Have a positive urine drug screen for any substance of abuse or excluded medication\n\n          -  Have serious cardiovascular, hepatic, renal, respiratory, or hematologic illness, or\n             other medical or psychiatric condition that, in the opinion of the investigator,\n             would compromise participation or be likely to lead to hospitalization during the\n             course of the study\n\n          -  Have a history of recurrent seizures other than febrile seizures\n\n          -  Are judged clinically by the investigator to be at suicidal risk according to the\n             Columbia - Suicide Severity Rating Scale (C-SSRS): a \"Yes\" answer to either Question\n             4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) or\n             Question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the\"Suicidal\n             Ideation\" portion of the C-SSRS or a \"Yes\" answer to any of the suicide related\n             behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory act or\n             behavior) on the \"Suicidal Behavior\" portion of the C-SSRS, with the\n             ideation/behavior having occurred within the previous month\n\n          -  Have uncontrolled narrow-angle glaucoma\n\n          -  Have acute liver injury (such as hepatitis) or severe\n\n          -  Have known hypersensitivity to duloxetine or any of the inactive ingredients or have\n             frequent/severe allergic reactions to multiple medications\n\n          -  Have frequent falls that could result in hospitalization or could compromise response\n             to treatment\n\n          -  Have a diagnosis of inflammatory arthritis [that is, rheumatoid arthritis (RA)] or an\n             autoimmune disorder (excluding inactive Hashimoto's thyroiditis)\n\n          -  Have received intra-articular hyaluronate/steroids, joint lavage, or other invasive\n             therapies to the index joint in the previous 3 months\n\n          -  Have had arthroscopy of the index joint within the previous year or joint replacement\n             of the index joint at any time\n\n          -  Have surgery of the index joint scheduled to occur during the trial or are\n             anticipated by the investigator to require surgery for the treatment of the OA of the\n             index hip or knee along the duration of the study\n\n          -  Have had a prior synovial fluid analysis showing a white blood cell (WBC) count\n             \u22652000 cubic millimeter (mm3) that is indicative of a diagnosis other than OA\n\n          -  Are non-ambulatory or require the use of crutches or a walker\n\n          -  Have a body mass index >40\n\n          -  Are anticipated by the investigator to require use of analgesic agents including, but\n             not limited to, nonsteroidal anti-inflammatory drugs (NSAIDs),\n             acetaminophen/paracetamol, and opioids, or other excluded medication for the duration\n             of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01931475", 
            "org_study_id": "13494", 
            "secondary_id": "F1J-MC-HMGS"
        }, 
        "intervention": [
            {
                "arm_group_label": "Duloxetine", 
                "description": "Administered orally", 
                "intervention_name": "Duloxetine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "LY248686", 
                    "Cymbalta"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Administered orally", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Duloxetine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100029"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Bengbu", 
                        "country": "China", 
                        "zip": "233004"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Changchun", 
                        "country": "China", 
                        "zip": "130033"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China", 
                        "zip": "410013"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China", 
                        "zip": "610041"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Guang Zhou", 
                        "country": "China", 
                        "zip": "510515"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Hefei", 
                        "country": "China", 
                        "zip": "230022"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Pingxiang", 
                        "country": "China", 
                        "zip": "337055"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200433"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China", 
                        "zip": "110016"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "zip": "300052"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Duloxetine 60mg Once Daily in Patients With Chronic Pain Due to Osteoarthritis in China", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559)", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eil Lilly", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM-5PM Eastern Time (UTC/GMT-5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline to 13 Weeks in the Brief Pain Inventory (BPI) 24-hour Average Pain Rating", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 13 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01931475"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Patient Global Impressions of Improvement (PGI-I) at 13 Weeks", 
                "safety_issue": "No", 
                "time_frame": "13 Weeks"
            }, 
            {
                "measure": "Change from Baseline to 13 Weeks in Western Ontario and McMaster Universities Arthritis Index (WOMAC) Total and Subscale Scores", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 13 Weeks"
            }, 
            {
                "measure": "Change from Baseline to 13 Weeks in Clinical Global Impression of Severity (CGI-S)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 13 Weeks"
            }, 
            {
                "measure": "Change from Baseline to 13 Weeks in BPI Severity", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 13 Weeks"
            }, 
            {
                "measure": "Change from Baseline to 13 Weeks in Hospital Anxiety and Depression Scale-Depression (HADS-D) or HADS-Anxiety (HADS-A) Subscale Scores", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 13 Weeks"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}